Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

216.32
-1.7800-0.82%
Post-market: 216.320.00000.00%17:21 EST
Volume:698.80K
Turnover:151.69M
Market Cap:13.35B
PE:-48.97
High:221.80
Open:217.85
Low:213.02
Close:218.10
52wk High:242.00
52wk Low:124.06
Shares:61.70M
Float Shares:60.08M
Volume Ratio:0.69
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4176
EPS(LYR):-4.4176
ROE:-818.43%
ROA:-6.86%
PB:-69.16
PE(LYR):-48.97

Loading ...

Barclays Sticks to Its Buy Rating for Ascendis Pharma (ASND)

TIPRANKS
·
Feb 13

Ascendis Pharma NasdaqGS ASND Revenue Surge Keeps Losses In Focus And Tests Bullish Narratives

Simply Wall St.
·
Feb 13

Ascendis Pharma Shows Steady Progress Toward Long-Term Growth, Wedbush Says

MT Newswires Live
·
Feb 13

Ascendis Pharma Is Maintained at Outperform by Wedbush

Dow Jones
·
Feb 12

Wedbush Raises Price Target on Ascendis Pharma to $273 From $240, Keeps Outperform Rating

MT Newswires Live
·
Feb 12

Ascendis Pharma a/S : Oppenheimer Raises Target Price to $262 From $246

THOMSON REUTERS
·
Feb 12

RBC Capital Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Feb 12

Ascendis Pharma a/S : Stifel Raises Target Price to $325 From $256

THOMSON REUTERS
·
Feb 12

ASND: Strong Yorvipath Momentum and Pipeline Catalysts Underpin Buy Rating and Long‑Term Upside

TIPRANKS
·
Feb 12

Teijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment

Reuters
·
Feb 12

Earnings Flash (ASND) Ascendis Pharma Posts Q4 Loss -0.55 Euro, vs. FactSet Est of -0.19 Euro Loss

MT Newswires Live
·
Feb 12

Ascendis Pharma Q4 EPS $(0.64) Misses $(0.06) Estimate, Sales $288.127M Miss $289.720M Estimate

Benzinga
·
Feb 12

Ascendis Pharma reports FY 2025 net loss of EUR 228 million, narrowing 40%

Reuters
·
Feb 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 11

Health Canada genehmigt Yorvipath von Ascendis Pharma für die Behandlung von chronischem Hypoparathyreoidismus

Reuters
·
Feb 07

Ascendis Pharma A/S to Announce Full Year 2025 Financial Results and Business Update

Reuters
·
Feb 05

Ascendis Pharma price target raised to $260 from $246 at BofA

TIPRANKS
·
Jan 30

Ascendis Pharma Is Maintained at Buy by B of A Securities

Dow Jones
·
Jan 30

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading

MT Newswires Live
·
Jan 29

Ascendis Pharma Initiated at Overweight by Barclays

Dow Jones
·
Jan 28